Finding better ways to treat cancer
Finding better ways to
treat cancer
At Bolt, we are leveraging the immune system for a better way to treat cancer. Our approach works with a person’s body, not against it. We do this by using the innate immune system, which has evolved to recognize sequences associated with foreign invaders including bacteria, viruses, and fungi. Our various approaches use pattern recognition receptors in the innate immune system to help the body recognize tumor cells.
At Bolt, we are leveraging the immune system for a better way to treat cancer. Our approach works with a person’s body, not against it. We do this by using the innate immune system, which has evolved to recognize sequences associated with foreign invaders including bacteria, viruses, and fungi. Our various approaches use pattern recognition receptors in the innate immune system to help the body recognize tumor cells.
Bolt is pioneering a new approach, using myeloid cells and the innate immune system to create targeted immunotherapies. Our therapies can also activate the adaptive immune system.
Bolt is pioneering a new approach, using myeloid cells and the innate immune system to create targeted immunotherapies. Our therapies can also activate the adaptive immune system.
BDC-3042 is Bolt’s first-in-class Dectin-2 agonist antibody that works by repolarizing immune cells from tumor-supportive to tumor-destructive. It is currently being evaluated in a Phase 1 trial.
BDC-3042 is Bolt’s first-in-class Dectin-2 agonist antibody that works by repolarizing immune cells from tumor-supportive to tumor-destructive. It is currently being evaluated in a Phase 1 trial.
Our Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform has generated a number of product candidates, many through collaborations, combining various tumor-targeting antibodies and our myeloid biology expertise. We have also discovered and are developing an agonist antibody to repolarize macrophages.
Our Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform has generated a number of product candidates, many through collaborations, combining various tumor-targeting antibodies and our myeloid biology expertise. We have also discovered and are developing an agonist antibody to repolarize macrophages.
Our passionate and seasoned team of inventors, scientists and biotech builders is dedicated to generating breakthroughs for patients. Because our patients cannot wait.
Our passionate and seasoned team of inventors, scientists and biotech builders is dedicated to generating breakthroughs for patients. Because our patients can’t wait, and they shouldn’t have to.
